Andreas Fouras
Founder, MD, CEO & Director
Hi, everyone. Thank you so much for joining us today and for your interest in 4DMedical and today’s investor presentation. Of course, the key focus of today’s presentation is going to be CT:VQ post our announcement that we now have FDA approval for that product.
This is a transformational milestone for 4DMedical. CT:VQ is the world’s first and only non-contrast ventilation and perfusion imaging technology. We have an incredible addressable market. In the United States alone, there’s over 1 million nuclear VQ scans a year performed with a $1.1 billion U.S. market opportunity. And globally, we see that as being at least double that at USD 2.6 billion opportunity.
Furthermore, we really strongly feel that introduction of CT:VQ into the market will drive long-term growth in demand through both increased accessibility. There are far more CT scanners across the United States than there are nuclear scanners and through improved workflow and health economics for the providers. Additionally, and aligned with that, unlike rollouts of transformational technologies in the past, VQ is instantly scalable. There are already 14,500 CT scanners across the United States. Nobody needs to invest in new infrastructure to be able to deliver this game-changing technology.
So CT:VQ is set to displace nuclear VQ scans and expand functional imaging. And as part of our pathway to deliver that as rapidly as possible, I want to talk to you today about the clinical validation that we’ve performed and also the commercial traction already underway. CT:VQ, all the contrast, none of the injections. So we have a technology where there is no need for contrast agents. You have a clearer and faster diagnostic capability, enhanced access through a broad range of CT scanners, as I’ve said, in
Read the full article here